KRSA Korsana Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRSA

Price (delayed)

$32.3

Market cap

$21.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.67

Enterprise value

$20.21M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20
Highlights
Korsana Biosciences's EPS has plunged by 124% YoY and by 22% from the previous quarter
The quick ratio has plunged by 83% YoY and by 55% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cyclerion.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KRSA

KRSA stock price

How has the Korsana Biosciences stock price performed over time
Intraday
-7.66%
1 week
3.43%
1 month
18.62%
1 year
52.79%
YTD
263.33%
QTD
36.11%

Financial performance

How have Korsana Biosciences's revenue and profit performed over time
Revenue
$1.9M
Gross profit
$1.9M
Operating income
-$6.82M
Net income
-$6.71M
Gross margin
100%
Net margin
-353%
Korsana Biosciences's operating margin has plunged by 108% YoY and by 6% from the previous quarter
The operating income has plunged by 82% YoY
Korsana Biosciences's net margin has decreased by 33% from the previous quarter
The net income has declined by 27% since the previous quarter

Price vs fundamentals

How does KRSA's price correlate with its fundamentals

Growth

What is Korsana Biosciences's growth rate over time

Valuation

What is Korsana Biosciences stock price valuation
P/E
N/A
P/B
3.93
P/S
10.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.64
Korsana Biosciences's EPS has plunged by 124% YoY and by 22% from the previous quarter
The stock's price to book (P/B) is 183% more than its 5-year quarterly average of 1.5
The equity has contracted by 41% YoY and by 25% from the previous quarter
KRSA's P/S is 187% above its last 4 quarters average of 3.9
The revenue has declined by 13% year-on-year and by 4.7% since the previous quarter

Efficiency

How efficient is Korsana Biosciences business performance
The company's return on equity fell by 42% QoQ
The return on invested capital has declined by 40% since the previous quarter
KRSA's return on assets is down by 36% since the previous quarter
Korsana Biosciences's ROS has decreased by 33% from the previous quarter

Dividends

What is KRSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRSA.

Financial health

How did Korsana Biosciences financials performed over time
Korsana Biosciences's total liabilities has soared by 130% YoY and by 8% from the previous quarter
The current ratio has plunged by 84% YoY and by 54% from the previous quarter
Korsana Biosciences's debt is 100% less than its equity
The equity has contracted by 41% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.